Tencent's Hunyuan Research Agent version 2.0 made its debut Monday, claiming to have crossed a threshold that has defined the ambition of AI-for-science research for a decade: instead of solving ...

What runs on the screens of websites and web services is JavaScript inside the viewer's browser. However, during the development phase of those pages, "Node.js," which runs outside the browser, is ...

There Is Something We Have to Do Right Now About A.I. Artificial intelligence labs are on the verge of handing over the training of A.I. to A.I. We should stop them. There’s a chasm right now between ...

AI agents are not yet creative enough to carry out genuinely innovative open-ended AI research, it seems. The AI industry’s boldest promise right now is that AI will soon improve itself, with almost ...

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and ...

Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an early test of whether artificial intelligence can uncover new medicines.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Decision tree regression is a fundamental machine learning technique to predict a single numeric value. A decision tree regression system incorporates a set of virtual if-then rules to make a ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...

Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...

Recursion said it will end development for four of its 11 pipeline programs—one of which the company will consider outlicensing to a partner instead—and pause a fifth program, in a pruning designed to ...